WeForNews | Latest News, Breaking News, News Updates Elite US surgeon to train Indian doctors in robotic surgery | WeForNews | Latest News, Blogs
Connect with us

Health

Elite US surgeon to train Indian doctors in robotic surgery

Published

on

doctors-wefornews
file name

A leading US robotic surgeon, Dr. Chris Holsinger from Stanford, will appoint in India this week to train head and neck surgeons on minimally invasive methods such as robotic surgery for treating cancer patients.

India with its vast number of smoking population is home to the largest number of head and neck cancer patients in the world that go untreated.

Indian Council of Medical Research (ICMR) studies reveal that in India over 200,000 head and neck cancers are reported each year. Of these, nearly three-fourth cancers relate to oral cavity, throat and voice box.

Holsinger, who leads Stanford Cancer Centre’s Head and Neck Oncology practice will share his vast experience at the Second National Workshop in Transoral Surgery at Delhi’s Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC) on Saturday.

During the day-long session Holsinger, widely recognised as the global guru of head and neck surgery, will speak to over a 100 surgeons on the ‘How, When and When Not’ of robotic surgery, according to a media release.

The audience will include surgeons from All India Institute of Medical Sciences (AIIMS), Medanta Medicity, Maulana Azad Medical College (MAMC), Sir Ganga Ram Hospital and Post Graduate Institute of Medical Research (PGI).

In addition, he along with workshop co-chair and consultant surgical oncologist RGCIRC Dr Surender Dabas will also conduct robotic surgeries that will be telecast live to the attendees at the event.

The conference will debate issues like relative merits and demerits of radiotherapy versus robotic surgery as a method to treat mouth and pharynx cancer patients.

Since 80 per cent of Indian patients test negative for Human Papilloma Virus (HPV), robotic surgery leads to better results compared to radiotheraphy.

“While smokers have a 16 times higher risk of contracting oral cancer, the risk factor grows to 36 times among smokers who consume alcohol,” said Dabas who has conducted over 200 robotic surgeries in the last two years.

“Participation of patients in preventive health check ups is key to controlling this menacing medical condition,” said Dr AK Dewan, medical director and Chief of Head and Neck surgery, RGCIRC.

Holsinger, founded and led the programme in Minimally Invasive and Endoscopic Head and Neck Surgery at the University of Texas’ MD Anderson Cancer Centre before founding the programme in robotic surgery at Stanford.

RGCIRC’s oncology practice in Head and Neck, Urology, Gynaecology, Thoracic and General area has recorded over 1500 robotic surgeries since introduction in early 2011.

“Robotic procedures in India are estimated to cross the 6000 mark in 2015 as more and more procedures across the spectrum have started using robots,” said Dr Mahendra Bhandari, CEO of the US headquartered Vattikuti Foundation that is promoting prevention and treatment of cancer in USA and India.

wefornews bureau

Cities

Delhi reports 51 cases of minor adverse events post vaccination

As many as 1,91,181 people were vaccinated on day one of India’s first phase of the coronavirus vaccination drive.

Published

on

By

Covid 19 Vaccine

Hours after the Health Ministry announced on January 16 that India has reported no case of post-vaccination hospitalisation yet, 51 persons complained of minor adverse events in Delhi. Another person developed severe adverse event following immunization and had to be referred to the AEFI centre.

Out of a total of 4,319 healthcare and frontline workers who were vaccinated on Jnauary 16 in the National Capital, two healthcare workers at NDMC’s Charak Palika Hospital reported mild adverse event post-vaccination including mild tightness in the chest. They were kept under observation by AEFI team and discharged 30 minutes later after they felt at ease. The two other cases were reported from Northern Railway Central Hospital, of which one was referred to the AEFI centre, the Delhi government has informed.

As many as 1,91,181 people were vaccinated on day one of India’s first phase of the coronavirus vaccination drive.

Beneficiaries from 11 states and union territories across India received Covishield or Covaxin shots on the first day of the vaccination drive, namely, Assam, Bihar, Delhi, Haryana, Karnataka, Maharashtra, Odisha, Rajasthan, Tamil Nadu, Telangana, and Uttar Pradesh.

Follow our coverage of the coronavirus crisis here

Continue Reading

Health

Bharat Biotech to pay compensation if Covaxin causes side-effects

The vaccine maker said in phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19

Published

on

By

COVAXIN Corona Covid vaccine

Hyderabad, January 16: Bharat Biotech, which has received a government purchase order for supply of 55 lakh doses of Covaxin, a COVID-19 vaccine, said the company would pay compensation to recipients in case of any serious adverse effects experienced after receiving the antidote.

In the consent form to be signed by the vaccine recipients, Bharat Biotech said: “In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres/hospitals.”

“The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine,” the consent form said.

In phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19. However, the clinical efficacy of the vaccine was yet to be established and it was still being studied in phase 3 clinical trials, the vaccine maker said.

“Hence it is important to appreciate that receiving the vaccine does not mean that other precautions related to COVID-19 need not be followed,” the consent form said.

According to an industry expert, the company is liable to pay compensation to people in case of serious side effects as the vaccine is being administered while in the clinical trial mode.

The central licensing authority has granted permission for the sale or distribution of Covaxin for restricted use in emergency situations in public interest as an abundant caution, in clinical trial mode.

Meanwhile, Suchitra Ella, joint managing director, Bharat Biotech International Limited, on her Twitter account said: “Covaxin & Bharat Biotech is truly humbled & honoured to be of service to the nation & the fraternity of all first responders of covid who have served public health.” — PTI

Continue Reading

Cities

AIIMS security guard reports allergy post COVID vaccination, in hospital care

Delhi has reported 52 adverse events following events of which one is serious and could involve the guard hospitalised today.

Published

on

By

Vaccine

New Delhi, January 16

A 22-year-old security guard at AIIMS, New Delhi reported allergic reaction and is learnt to be in intensive care, moments after the government said there was no post-vaccine hospitalisation.

The 22-year-old guard developed headache, rash, respiratory distress, tachycardia after vaccination. He is in ICU and his condition is stable, hospital sources said.

Delhi has reported 52 adverse events following events of which one is serious and could involve the guard hospitalised today.

All beneficiaries vaccinated at AIIMS got indigenous COVAXIN.

Continue Reading
Advertisement

Most Popular